Diversified Trust Co Sells 6,261 Shares of Insulet Corporation $PODD

Diversified Trust Co reduced its position in Insulet Corporation (NASDAQ:PODD) by 77.3% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 1,841 shares of the medical instruments supplier’s stock after selling 6,261 shares during the period. Diversified Trust Co’s holdings in Insulet were worth $386,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of PODD. Larson Financial Group LLC raised its stake in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. bought a new position in shares of Insulet during the 4th quarter worth approximately $26,000. Elyxium Wealth LLC bought a new position in shares of Insulet during the 4th quarter worth approximately $28,000. DV Equities LLC acquired a new position in shares of Insulet during the 4th quarter worth approximately $28,000. Finally, MV Capital Management Inc. acquired a new position in shares of Insulet during the 4th quarter worth approximately $29,000.

Insiders Place Their Bets

In related news, Director Timothy C. Stonesifer bought 2,790 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, with a total value of $400,392.90. Following the completion of the purchase, the director owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 0.36% of the stock is owned by corporate insiders.

Insulet Stock Up 2.9%

PODD stock opened at $158.25 on Friday. The firm has a 50-day moving average price of $159.09 and a 200-day moving average price of $220.64. Insulet Corporation has a 12 month low of $138.79 and a 12 month high of $354.88. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $10.96 billion, a P/E ratio of 36.80, a price-to-earnings-growth ratio of 1.07 and a beta of 1.13.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm’s revenue was up 33.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities research analysts anticipate that Insulet Corporation will post 6.46 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Wall Street Zen downgraded Insulet from a “strong-buy” rating to a “buy” rating in a report on Saturday. Sanford C. Bernstein decreased their price objective on shares of Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Piper Sandler dropped their price objective on shares of Insulet from $360.00 to $210.00 in a research report on Wednesday, May 6th. The Goldman Sachs Group reissued a “buy” rating and issued a $205.00 price objective on shares of Insulet in a research report on Wednesday, May 27th. Finally, Rothschild & Co Redburn reaffirmed a “neutral” rating and set a $220.00 target price (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Twenty-two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $238.67.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.